TY - JOUR
T1 - Targeting the gatekeeper
T2 - Osimertinib in EGFR T790M mutation-positive non-small cell lung cancer
AU - Skoulidis, Ferdinandos
AU - Papadimitrakopoulou, Vassiliki A.
N1 - Funding Information:
V.A. Papadimitrakopoulou reports receiving commercial research grants from AstraZeneca, Bayer, Bristol-Myers Squibb, Celgene, Clovis Oncology, Genentech, Janssen, Merck, Novartis, and Pfizer and is a consultant/advisory board member for ARAD, AstraZeneca, Genentech, Janssen, and Merck. No potential conflicts of interest were disclosed by the other author. F. Skoulidis is supported by the Andrew Sabin Family Foundation, the Lung Cancer Research Foundation, a Sheikh Khalifa Bin Zayed Al Nahyan Scholar Award, and generous philanthropic contributions to the University of Texas Lung Moon Shot Program.
Publisher Copyright:
©2016 AACR.
PY - 2017/2/1
Y1 - 2017/2/1
N2 - In 2015, the FDA approved an unprecedented number of new therapies for non-small cell lung cancer (NSCLC), among them therapies addressing specific genomic tumor subsets in the setting of development of resistance to first-line targeted therapy. Osimertinib (Tagrisso, formerly AZD9291; AstraZeneca) is indicated for patients with metastatic EGFR T790M mutation-positive NSCLC, as detected by an FDA-approved test, who have progressed on or after EGFR tyrosine kinase inhibitor therapy. It received breakthrough therapy designation, priority review status, and accelerated approval from the FDA.
AB - In 2015, the FDA approved an unprecedented number of new therapies for non-small cell lung cancer (NSCLC), among them therapies addressing specific genomic tumor subsets in the setting of development of resistance to first-line targeted therapy. Osimertinib (Tagrisso, formerly AZD9291; AstraZeneca) is indicated for patients with metastatic EGFR T790M mutation-positive NSCLC, as detected by an FDA-approved test, who have progressed on or after EGFR tyrosine kinase inhibitor therapy. It received breakthrough therapy designation, priority review status, and accelerated approval from the FDA.
UR - http://www.scopus.com/inward/record.url?scp=85012303883&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85012303883&partnerID=8YFLogxK
U2 - 10.1158/1078-0432.CCR-15-2815
DO - 10.1158/1078-0432.CCR-15-2815
M3 - Review article
C2 - 27821604
AN - SCOPUS:85012303883
SN - 1078-0432
VL - 23
SP - 618
EP - 622
JO - Clinical Cancer Research
JF - Clinical Cancer Research
IS - 3
ER -